{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:15:15Z","timestamp":1792800915978,"version":"4.5.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T00:00:00Z","timestamp":1789689600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have transformed cancer treatment, but immune-related adverse events remain clinically challenging. Tislelizumab is a humanized anti-PD-1 monoclonal antibody widely used in China, and tislelizumab-associated secondary adrenal insufficiency (SAI) remains insufficiently characterized, particularly with regard to how and when it is recognized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>A 66-year-old man underwent video-assisted thoracoscopic surgery for right lower lobe squamous cell carcinoma (pT1cN1M0, stage IIB), followed by four cycles of carboplatin, paclitaxel liposome and tislelizumab, then 13 cycles of tislelizumab maintenance. His last tislelizumab dose was administered on December 11, 2023. Poor appetite and fatigue first developed in November 2023, accompanied by a blood pressure of 92\/57 mmHg. His symptoms improved after supportive treatment, but adrenocorticotropic hormone (ACTH) and cortisol were not measured. He subsequently developed headache, nausea, vomiting, and progressive weight loss of 19\u00a0kg. In November 2024, he was admitted with hypotension (75\/56 mmHg) and severe hyponatremia (108.9 mmol\/L); chest CT and bronchoscopy excluded tumor recurrence, and he improved with supportive care. Symptoms recurred within a week of discharge, and he was readmitted in December 2024 with hypotension (52\/37 mmHg) and recurrent hyponatremia. On December 11, 2024, approximately 13 months after the initial symptoms, morning cortisol was &amp;lt;1.00 \u00b5g\/dL and ACTH was inappropriately low at &amp;lt;5.00 pg\/mL, supporting SAI (Naranjo score 6, probable). Pituitary MRI, cosyntropin stimulation testing and comprehensive pituitary hormonal assessment were unavailable; hypophysitis was therefore not confirmed, and the site of hypothalamic-pituitary-adrenal (HPA) axis injury could not be determined. He improved with intravenous hydrocortisone and fluids and was transitioned to oral prednisone. ACTH and cortisol remained low through July 2025 during replacement, although endogenous HPA-axis recovery could not be reliably assessed. At telephone follow-up in June 2026 no recurrent adrenal crisis was reported.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Tislelizumab-associated SAI may present with nonspecific symptoms and remain unrecognized until adrenal crisis develops, including months after the last dose. Unexplained fatigue, gastrointestinal symptoms, weight loss, hyponatremia, hypoglycemia, or hypotension should prompt early measurement of paired morning ACTH and cortisol levels. Prompt glucocorticoid replacement and structured endocrine follow-up are essential for patient safety and assessment of potential HPA-axis recovery.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fendo.2026.1915283","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:32:03Z","timestamp":1789705923000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Case Report: Tislelizumab-associated secondary adrenal insufficiency in a patient with lung squamous cell carcinoma"],"prefix":"10.3389","volume":"17","author":[{"given":"Zongsheng","family":"Tian","sequence":"first","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanghui","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Kong","sequence":"additional","affiliation":[{"name":"Department of Hyperbaric Oxygen Medicine, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueliang","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Respiratory and Critical Care Medicine, Linyi People\u2019s Hospital","place":["Linyi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,18]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2025.115339","article-title":"Aptamers as immune checkpoint inhibitors in cancer immunotherapy: Targeting Ctla-4\/B7 and Pd-1\/Pd-L1 pathways","volume":"164","author":"Anantha Rajah","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar4060","article-title":"Cancer immunotherapy using checkpoint blockade","volume":"359","author":"Ribas","year":"2018","journal-title":"Science"},{"key":"B3","doi-asserted-by":"publisher","first-page":"276","DOI":"10.3390\/ph19020276","article-title":"Immune-related adverse events associated with immune checkpoint inhibitors: A scoping review","volume":"19","author":"Tacchi","year":"2026","journal-title":"Pharm (Basel)"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.03.023","article-title":"Endocrinopathies associated with immune checkpoint inhibitor use","volume":"30","author":"Kotwal","year":"2024","journal-title":"Endocr Pract"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2025.1636452","article-title":"Initial symptoms and diagnostic delay in immune checkpoint inhibitor-related adrenal insufficiency: A systematic review and meta-ethnography of case reports","volume":"16","author":"Ohta","year":"2025","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01286-z","article-title":"Tislelizumab: first approval","volume":"80","author":"Lee","year":"2020","journal-title":"Drugs"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2025.5485","article-title":"Adrenal insufficiency in adults: A review","volume":"334","author":"Vaidya","year":"2025","journal-title":"JAMA"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/clpt.1981.154","article-title":"A method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin Pharmacol Ther"},{"key":"B9","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-22-0689","article-title":"Endocrine-related adverse conditions in patients receiving immune checkpoint inhibition: An Ese clinical practice guideline","volume":"187","author":"Husebye","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00136-7","article-title":"Adrenal insufficiency","volume":"397","author":"Husebye","year":"2021","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2022.7098","article-title":"Hypophysitis and secondary adrenal insufficiency from immune checkpoint inhibitors: Diagnostic challenges and link with survival","volume":"21","author":"Johnson","year":"2023","journal-title":"J Natl Compr Canc Netw"},{"key":"B12","doi-asserted-by":"publisher","first-page":"230ra45","DOI":"10.1126\/scitranslmed.3008002","article-title":"Pituitary expression of Ctla-4 mediates hypophysitis secondary to administration of Ctla-4 blocking antibody","volume":"6","author":"Iwama","year":"2014","journal-title":"Sci Transl Med"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-19-0238","article-title":"Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis","volume":"181","author":"Faje","year":"2019","journal-title":"Eur J Endocrinol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002493","article-title":"Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint inhibitors","volume":"9","author":"Kobayashi","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1908079116","article-title":"Autoimmune antibodies correlate with immune checkpoint therapy-induced toxicities","volume":"116","author":"Tahir","year":"2019","journal-title":"Proc Natl Acad Sci USA"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1284301","article-title":"Paraneoplastic isolated adrenocorticotropic hormone deficiency revealed after immune checkpoint inhibitors therapy: New insights into anti-corticotroph antibody","volume":"14","author":"Urai","year":"2023","journal-title":"Front Immunol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1295310","article-title":"Adrenal crisis mainly manifested as recurrent syncope secondary to tislelizumab: A case report and literature review","volume":"14","author":"Wei","year":"2024","journal-title":"Front Immunol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.51015","article-title":"Immunotherapy-induced hypophysitis following treatment with tislelizumab in an elderly patient with bladder cancer and prostate cancer: A case report","volume":"15","author":"Zhang","year":"2023","journal-title":"Cureus"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000037562","article-title":"Immune checkpoint inhibitor-related adrenal hypofunction and psoriasisby induced by tislelizumab: A case report and review of literature","volume":"103","author":"Deng","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1516297","article-title":"Case report: Robust and durable response to the combination of tislelizumab and chemotherapy in advanced thymic epithelial tumors: A case series","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.12659\/AJCR.948143","article-title":"Hypophysitis induced by tislelizumab: A case report of somnolence and delirium with elevated eosinophils","volume":"26","author":"Hu","year":"2025","journal-title":"Am J Case Rep"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1159\/000546423","article-title":"Prolonged progression-free survival in a patient with highly pretreated recurrent ovarian cancer after developing multisystem immune-related adverse events: A case report and literature review","volume":"18","author":"Liu","year":"2025","journal-title":"Case Rep Oncol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000048449","article-title":"Multiple endocrine adverse reactions and pituitary axis dysfunction induced by Pd-1 immunotherapy in an esophageal cancer patient: Case report","volume":"105","author":"Sheng","year":"2026","journal-title":"Med (Baltimore)"},{"key":"B24","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1186\/s12890-024-03140-4","article-title":"Pituitary-adrenal axis dysfunction induced by tislelizumab immunotherapy for non-small cell lung cancer: A case series and literature review","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Pulm Med"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.12701\/yujm.2021.00934","article-title":"Adrenal insufficiency development during chemotherapy plus anti-programmed death receptor-1 monoclonal antibody (Tislelizumab) therapy in patients with advanced gastric cancer: Two case reports","volume":"39","author":"Baek","year":"2022","journal-title":"J Yeungnam Med Sci"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1915283\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:32:28Z","timestamp":1789705948000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1915283\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":25,"alternative-id":["10.3389\/fendo.2026.1915283"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1915283","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,18]]},"article-number":"1915283"}}